CTRI/2018/06/014614
Completed
未知
Development of a dosing algorithm using pharmacogenetic and clinical variables for optimizing anticoagulant therapy in patients on warfarin.
Dr Nusrat Shafiq0 sites82 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- atrial fibrillation and valve replacement patients requiring chronic anticoagulation therapy
- Sponsor
- Dr Nusrat Shafiq
- Enrollment
- 82
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients of atrial fibrillation and patients requiring valve replacement surgeries on chronic anticoagulation therapy with warfarin
Exclusion Criteria
- •1\. Patients with known contraindications to anticoagulant therapy,
- •2\. Patients of transient atrial fibrillation secondary to reversible disorders such as thyrotoxicosis, cardiothoracic surgery and severe anaemia,
- •3\. Patients with underlying hepatic (defined as elevation in alanine/ aspartate transaminase \>2\.5 times the upper limit of normal) and or severe renal insufficiency(defined as creatinine clearance of \<30ml/min),
- •4\. Pregnant and nursing women,
- •5\. Patients unwilling to participate in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Implementation of pharmacokinetic-guided dosing of prophylaxis in hemophilia patients.HemophiliaMedDRA version: 20.0 Level: LLT Classification code 10060614 Term: Hemophilia B (Factor IX) System Organ Class: 100000004850MedDRA version: 20.0 Level: LLT Classification code 10060613 Term: Hemophilia A (Factor VIII) System Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2018-003869-33-NLErasmus University Medical Center50
Not yet recruiting
Not Applicable
Implementation of pharmacokinetic-guided dosing of prophylaxis in hemophilia patientsNL-OMON27791Erasmus Medical Center, Sophia Children's Hospital50
Not yet recruiting
Not Applicable
Implementation of pharmacokinetic-guided dosing of prophylaxis in hemophilia patients.NL-OMON55874Erasmus MC, Universitair Medisch Centrum Rotterdam50
Recruiting
Not Applicable
Implementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand diseaseNL-OMON54546Erasmus MC, Universitair Medisch Centrum Rotterdam160
Active, not recruiting
Phase 1
Effects of pharmacokinetic models in dosing of DDAVP and/or von Willebrand factor-containing concentrates in patients with von Willebrand diseaseVon Willebrand diseaseMedDRA version: 20.0Level: LLTClassification code 10055168Term: Von Willebrand's factor deficiencySystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2018-001631-46-NLErasmus University Medical Center120